MKK900

· MAXVAX Biotechnology Limited Liability Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MKK900, covering 2026-03-25 to 2026-03-25. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women [Phase 1]

See pricing